Interferon Kappa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Interferon Kappa
DrugBank Accession Number
DB15749
Background

Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Interferons
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • IFN‐κ
External IDs
  • Interferon Kappa

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Significant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN-κ acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN-κ binds at the same receptors, which are interferon-α/β receptor 1(IFNAR1) and IFNAR2.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Interferon Kappa.
BromotheophyllineThe metabolism of Bromotheophylline can be decreased when combined with Interferon Kappa.
CaffeineThe metabolism of Caffeine can be decreased when combined with Interferon Kappa.
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Interferon Kappa.
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Interferon Kappa.
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Interferon Kappa.
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Interferon Kappa.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Interferon Kappa.
ZidovudineThe risk or severity of adverse effects can be increased when Interferon Kappa is combined with Zidovudine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V, Chen G, Ruben SM, Pitha PM, Coleman TA, Moore PA: Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001 Oct 26;276(43):39765-71. doi: 10.1074/jbc.M102502200. Epub 2001 Aug 20. [Article]
  2. de Weerd NA, Nguyen T: The interferons and their receptors--distribution and regulation. Immunol Cell Biol. 2012 May;90(5):483-91. doi: 10.1038/icb.2012.9. Epub 2012 Mar 13. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 21:55 / Updated on August 13, 2020 07:02